Vyleesi Cost in Colorado 2026: Cash Price, Insurance, Compounded Options

What Is Vyleesi and Who Is It For?

Bremelanotide, sold under the brand name Vyleesi, is an FDA-approved melanocortin receptor agonist indicated for hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. The FDA granted approval in June 2019 based on the phase 3 RECONNECT program. HSDD is characterized by persistently low sexual desire that causes personal distress, and it affects an estimated 8 to 10 percent of adult women in the United States [2].

Unlike flibanserin (Addyi), which is taken daily, bremelanotide is used on an as-needed basis. Patients self-administer a 1.75 mg subcutaneous injection with an autoinjector device approximately 45 minutes before anticipated sexual activity. The drug works by activating MC1R and MC4R melanocortin receptors in the central nervous system, a mechanism distinct from hormonal therapies [3].

The RECONNECT trials enrolled premenopausal women with a diagnosis of generalized, acquired HSDD. Both key studies used the Female Sexual Function Index desire domain and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) as co-primary endpoints [4]. Patients who did not respond to prior psychotherapy were still eligible, broadening the real-world applicability of the data.

Bremelanotide is not approved for postmenopausal women, for men, or for any sexual dysfunction other than HSDD. Prescribers in Colorado should review the full FDA label before initiating therapy, particularly the contraindication for patients with pre-existing cardiovascular disease due to transient blood pressure increases observed in clinical trials [1].

Vyleesi Brand Price in Colorado 2026

The brand-name cash price for Vyleesi in Colorado sits at approximately $1,200 per month in 2026. That figure represents the manufacturer's wholesale acquisition cost and closely tracks what most Colorado retail pharmacies charge a cash-paying patient without insurance benefits.

A single autoinjector delivers one 1.75 mg dose. Because the drug is used "as needed," the monthly cost varies with how often a patient uses it. Palatin Technologies packages four autoinjectors per carton, which is the standard dispensing unit. At $1,200 for four injectors, each dose costs roughly $300 [1].

Prices at major Colorado retail chains, including King Soopers Pharmacy, Walgreens, and Safeway Pharmacy, typically mirror or slightly exceed wholesale acquisition cost for brand biologics and specialty drugs. GoodRx and similar discount platforms offer minimal savings on this product category because bremelanotide has no generic equivalent and limited pharmacy competition.

For Colorado patients without adequate insurance coverage, the brand cash price places Vyleesi beyond reach for many households. The median household income in Colorado was approximately $87 to 598 in 2023 according to U.S. Census data, meaning $1,200 per month represents roughly 16 percent of average monthly pre-tax income [5]. That affordability gap explains why compounded alternatives and manufacturer savings programs receive significant patient interest.

RECONNECT Trial Efficacy Data

The RECONNECT phase 3 program, published in Obstetrics and Gynecology in 2019, provides the primary clinical evidence for bremelanotide [4]. Two identically designed randomized, double-blind, placebo-controlled trials enrolled a combined 1,267 premenopausal women with HSDD.

In both studies, bremelanotide produced statistically significant improvements over placebo on both co-primary endpoints. Specifically, 25.0 percent of bremelanotide-treated patients achieved a clinically meaningful improvement in the FSDS-DAO distress score, compared with 17.0 percent of placebo patients in study one (P<0.001) [4]. The FSFI desire domain showed a parallel benefit. Nausea was the most common adverse effect, reported by 40 percent of bremelanotide patients versus 1 percent of placebo patients. Transient decreases in systolic blood pressure and transient elevations in diastolic blood pressure were also observed [4].

The FDA label notes that the mean increase in diastolic blood pressure was approximately 1.1 mmHg above placebo, but individual patients can experience larger transient elevations [1]. For Colorado patients who live at high altitude, particularly those above 5,000 feet, clinicians may want to check baseline blood pressure before prescribing, although no altitude-specific dosing guidance exists in current labeling.

A secondary analysis of RECONNECT data examined patient-reported satisfaction with the autoinjector device. Over 80 percent of participants reported the device was easy to use after a single training session, which is relevant for telehealth-initiated prescriptions where in-person device instruction is not provided [4].

Colorado Medicaid Coverage for Vyleesi

Colorado Medicaid does not cover Vyleesi for HSDD. The Colorado Department of Health Care Policy and Financing (HCPF) restricts bremelanotide coverage to type 2 diabetes-related melanocortin indications, a category that does not apply to standard HSDD prescriptions [6].

This coverage gap is consistent with national Medicaid trends. A 2021 analysis published in JAMA Internal Medicine found that FDA-approved medications for female sexual dysfunction faced higher prior-authorization barriers and lower formulary inclusion rates than comparable medications approved for male sexual dysfunction [7]. Colorado Medicaid's non-coverage of Vyleesi for HSDD fits that documented pattern.

Patients enrolled in Colorado Medicaid who need HSDD treatment have limited publicly funded options. Flibanserin (Addyi) faces similar Medicaid coverage restrictions in Colorado. Providers working with low-income premenopausal women in Colorado may consider referring patients to Palatin's patient assistance program or to 503A compounding pharmacies where cost is substantially lower.

A formal appeal or prior authorization request for Vyleesi through Colorado Medicaid is unlikely to succeed under current coverage policy. The coverage policy is reviewed annually, so the 2026 status may differ from 2025; patients should verify current status at Colorado HCPF's pharmacy benefits portal before assuming non-coverage [6].

Which Commercial Insurance Plans Cover Vyleesi in Colorado?

Coverage varies by plan and employer. Several major commercial insurers active in Colorado include Vyleesi on specialty tier formularies with prior authorization requirements. Cigna, Anthem Blue Cross Blue Shield of Colorado, and UnitedHealthcare all maintain active specialty formularies that have included bremelanotide in prior plan years, though tier placement and prior authorization criteria shift annually [8].

Prior authorization criteria typically require documentation of a formal HSDD diagnosis, confirmation of premenopausal status, absence of contraindications (particularly cardiovascular disease), and sometimes evidence that a trial of psychotherapy or other first-line therapy was attempted [1]. Step therapy requirements for flibanserin before Vyleesi are uncommon but not unheard of in Colorado plans.

Out-of-pocket costs for commercially insured Colorado patients depend on their specific plan's specialty drug tier copay. Specialty tier copays in Colorado plans ranged from $50 to $150 per fill in 2025 for comparable specialty medications, according to Kaiser Family Foundation employer health benefit survey data [9]. With the Palatin savings card applied on top of insurance, eligible patients may pay $0 per month (see savings card section below).

Colorado is subject to the Affordable Care Act's prohibition on discriminatory formulary design. Patients who believe their insurer is applying higher barriers to female sexual dysfunction drugs than to comparable male sexual dysfunction drugs may file a complaint with the Colorado Division of Insurance [10].

Compounded Bremelanotide in Colorado: Legality and Cost

Compounded bremelanotide from a licensed 503A pharmacy is legal in Colorado. Federal law under the Drug Quality and Security Act (21 U.S.C. 503A) permits state-licensed compounding pharmacies to prepare patient-specific prescriptions for compounded drugs, including those with FDA-approved brand equivalents, provided the compounding pharmacy meets all USP standards and state licensing requirements [11].

Colorado's Board of Pharmacy licenses 503A compounding pharmacies under Colorado Revised Statutes Title 12, Article 280. A valid, patient-specific prescription from a licensed Colorado prescriber is required. Bulk compounding of bremelanotide without a patient-specific prescription would not comply with 503A requirements [11].

The cost difference is substantial. Compounded bremelanotide from a licensed Colorado 503A pharmacy runs approximately $140 per month, compared with $1,200 per month for brand Vyleesi. That represents an 88 percent cost reduction. For a patient using two to four injections per month, compounded product pricing typically ranges from $50 to $150 per month depending on the pharmacy and concentration specified.

Quality considerations apply. Compounded drugs are not FDA-approved, meaning they have not undergone the same manufacturing consistency, sterility, and potency verification as the brand product. Patients should confirm that their compounding pharmacy holds current Colorado Board of Pharmacy licensure, conducts sterility testing, and follows USP 797 standards for sterile preparations [12].

Telehealth providers in Colorado who prescribe compounded bremelanotide should document the medical rationale and the patient's acknowledgment that the compounded product differs from FDA-approved Vyleesi [1].

The Palatin Technologies Savings Card for Colorado Patients

Palatin Technologies offers a manufacturer copay savings program for commercially insured patients who are prescribed brand Vyleesi. The program is designed to reduce out-of-pocket costs to as low as $0 per month for eligible patients [13].

Eligibility requires that the patient have commercial insurance (not Medicaid, Medicare, or any other government-funded plan) and a valid prescription for Vyleesi. Colorado patients who meet these criteria can enroll directly through the Vyleesi savings program at the manufacturer's website. The card is presented at a participating retail pharmacy at the time of dispensing.

The savings card is not available for patients covered by Colorado Medicaid, Medicare Part D, or any other federally funded insurance program. This restriction is legally mandated under federal anti-kickback statutes [14]. Patients on government programs who cannot afford brand Vyleesi should ask their prescriber about Palatin's separate patient assistance program (PAP), which may provide free medication to qualifying low-income patients regardless of insurance type.

Savings cards for specialty medications frequently carry per-use caps, annual maximums, or expiration dates tied to calendar years. Colorado patients should review the current terms directly with Palatin Technologies, as card terms for 2026 may differ from prior years.

Telehealth Prescribing of Vyleesi in Colorado

Telehealth prescribing of Vyleesi is fully legal in Colorado. The Colorado Medical Practice Act permits telemedicine-based prescribing when the provider establishes a valid patient-provider relationship, which may be accomplished through a synchronous video visit [15].

Colorado's telemedicine parity law (C.R.S. 10-16-123) requires commercial insurers to reimburse covered telemedicine services at the same rate as in-person services. This means that a Colorado patient with commercial insurance who consults a telehealth provider about HSDD pays the same specialist copay whether the visit is conducted in-person or via video [15].

For bremelanotide specifically, the telehealth evaluation should include a structured HSDD assessment using a validated tool such as the Decreased Sexual Desire Screener (DSDS) or the FSFI, documentation of premenopausal status, cardiovascular history review, and blood pressure documentation [16]. Because bremelanotide causes transient blood pressure changes, some telehealth platforms require patients to submit a recent blood pressure reading before the initial prescription is transmitted [1].

HealthRX operates under Colorado telehealth prescribing rules and connects patients with board-certified providers who can evaluate HSDD, discuss both brand and compounded options, and send prescriptions to a Colorado pharmacy of the patient's choice, including 503A compounding pharmacies.

Prescriptions for Vyleesi do not require DEA Schedule II or III handling. Bremelanotide is not a controlled substance, which simplifies telehealth prescribing across Colorado county lines and removes the requirement for in-person visits that applies to Schedule II drugs [15].

Comparing the Four Cost Pathways for Colorado Patients

Colorado patients have four realistic cost pathways for bremelanotide in 2026.

Pathway 1: Brand cash pay. A patient without insurance pays approximately $1,200 per month at a Colorado retail pharmacy. No prior authorization is needed, but cost is prohibitive for most households.

Pathway 2: Brand with commercial insurance and savings card. A commercially insured patient with a plan that covers Vyleesi and the Palatin savings card applied may pay $0 to $50 per month depending on plan terms. This is the lowest-cost pathway for eligible patients, though prior authorization processing can take 5 to 10 business days [13].

Pathway 3: Compounded bremelanotide via 503A pharmacy. Approximately $140 per month. No insurance required. Requires a valid prescription and a licensed Colorado 503A pharmacy. Quality assurance depends on the individual pharmacy's practices.

Pathway 4: Brand with Colorado Medicaid. Not covered for HSDD. Patients on Medicaid should explore Pathway 3 or Palatin's PAP.

For most uninsured or Medicaid-enrolled Colorado patients, Pathway 3 (compounded 503A) offers the most accessible route to treatment in 2026. Commercially insured patients should pursue Pathway 2 before defaulting to cash pay.

Side Effects and Safety Considerations Relevant to Cost Decisions

Cost decisions should not be made in isolation from safety data. Nausea severe enough to affect daily function was reported by 18 percent of bremelanotide patients in RECONNECT versus 2 percent of placebo patients, and it occurred most often within one hour of injection [4]. Flushing affected 20 percent of active-treatment patients. Hyperpigmentation of the face, breasts, and gingiva was reported with repeated dosing [1].

The FDA label carries a warning about transient blood pressure changes. A mean decrease in systolic blood pressure of approximately 0.9 mmHg and a mean increase in diastolic pressure of approximately 1.1 mmHg occur within 12 hours of dosing. Patients with baseline hypertension or cardiovascular disease should not use bremelanotide [1].

Because the drug is used as needed rather than daily, patients who experience intolerable side effects can simply discontinue without tapering. This pharmacokinetic feature means that a patient trying one dose at the compounded $140-per-month price point faces lower financial risk than one who fills a full month of a daily oral medication before assessing tolerability.

The half-life of bremelanotide is approximately 2.7 hours. Patients should plan activity accordingly and avoid driving or operating machinery during the first hour after injection if they experience dizziness or hypotension [1].

Altitude Considerations for Colorado Patients

Colorado patients living above 5,000 feet elevation face a unique clinical consideration not addressed in any current Vyleesi labeling. High-altitude residence is associated with lower resting diastolic blood pressure and increased sympathetic tone in some individuals [17]. Given bremelanotide's known transient diastolic blood pressure increase, the net hemodynamic effect at altitude has not been formally studied.

No published data directly address bremelanotide pharmacodynamics at high altitude. Colorado prescribers evaluating patients in Denver (5,280 feet), Boulder (5,430 feet), Colorado Springs (6,035 feet), or higher-elevation communities should document baseline blood pressure and consider a supervised first-dose observation, particularly in patients with any cardiac history. This is a clinical judgment call, not a labeled contraindication, and the FDA label does not restrict use by altitude [1].

How to Get a Vyleesi Prescription in Colorado in 2026

Getting a prescription in Colorado involves three steps. First, schedule a telehealth or in-person visit with a Colorado-licensed provider who is experienced with HSDD. Second, complete a structured HSDD assessment, including the DSDS or FSFI, blood pressure documentation, and a cardiovascular history review. Third, choose a dispensing pathway (brand retail, brand with savings card, or compounded 503A) based on insurance status and cost tolerance.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction recommends that HSDD diagnosis be based on DSM-5 criteria and that treatment decisions account for patient preference, comorbidities, and cost [18]. The guideline explicitly states: "Bremelanotide is an option for premenopausal women with HSDD when the patient and clinician agree that benefits outweigh potential risks" [18].

The North American Menopause Society (NAMS) 2022 position statement on sexual health notes that "both FDA-approved pharmacologic treatments for HSDD (flibanserin and bremelanotide) have modest but statistically significant efficacy compared with placebo and should be discussed as options alongside non-pharmacologic treatments" [19].

Patients who begin therapy through HealthRX telehealth receive a structured intake that documents HSDD diagnosis, blood pressure, cardiovascular contraindications, and insurance status before any prescription is transmitted. This documentation is required for insurance prior authorization and for compounding pharmacy dispensing.

Colorado patients who want the lowest cash-pay price should ask their HealthRX provider explicitly for a prescription written to allow dispensing by a 503A compounding pharmacy. A standard brand Vyleesi prescription can only be filled with the brand product at a retail pharmacy.